On August 7, Natera rose 13.05% overnight, trading at $300.01/share. The surge was driven by the company's Q2 earnings report that significantly exceeded market expectations on both top and bottom lines, accompanied by an upward revision of full-year revenue guidance.

Natera reported Q2 revenue of $752.8 million, up 37.7% year-over-year, substantially surpassing the analyst consensus estimate of approximately $661 million. Adjusted loss per share narrowed to $0.47, improving 36.5% from a loss of $0.74 in the year-ago quarter and beating the Street estimate of $0.49. The company simultaneously raised its full-year revenue guidance to $2.85 billion-$2.91 billion, above its prior forecast of $2.74 billion-$2.82 billion and the FactSet consensus of $2.80 billion.

The strong results come amid a series of positive catalysts for Natera's core Signatera MRD test, including EU IVDR Class C certification, Japan PMDA clearance for colorectal cancer, NCCN Category 1 recommendation in bladder cancer, and multiple phase 3 clinical partnerships with Aveta Biomics and Eledon Pharmaceuticals, reinforcing its leadership position in molecular residual disease testing.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)